PACE (Pathways to Antimicrobial Clinical Efficacy) has today launched its second funding round with up to £5 million available to support cutting-edge diagnostic projects. This funding is part of a broader £30 million investment to address the global challenge of antimicrobial resistance (AMR).

Paris, France - A new research study published in Nature Communications highlights how Depixus’ scalable single molecule technology can provide detailed mechanistic insights into RNA-ligand binding, supporting the development of novel therapeutics.

Based on magnetic force spectroscopy (MFS), Depixus’ large scale interactomics platform is the first analytical technology capable of exploring dynamic biomolecular interactions both in real time and from thousands of individual molecules in parallel.

Oxford, UK - British techbio innovator Etcembly has launched a groundbreaking new research study aiming to uncover new targets for cancer therapies by analysing the immune cells of cancer survivors.

The ETCh study is recruiting people aged 18-65 who are living with or have survived cancer to join the study, as well as healthy volunteers. Participants will be asked to donate a small amount of blood up to five times over the course of one year, and provide information about their health.

We invite you to join us for an afternoon in Cambridge MA, where we’ll be hosting an exclusive hands-on workshop featuring the latest release of Cresset’s ligand and structure-based drug design platform, Flare™. During this interactive session, you’ll explore key topics such as:

• Rapid approaches to new scaffold generation
• Qualitative analysis of structure-activity relationships (SAR)

Following the workshop, we will delve into how digital transformation is reshaping the industry and explore the ways in which Cresset is helping to catalyze that change.

AMSBIO has launched CellO-IF – an all-in-one immunofluorescent staining reagent kit designed to accelerate the labelling organoids and spheroids directly in hydrogels or extracellular matrices, while preserving delicate structures and cellular integrity.

Recent research indicates that the rate of global warming caused by human activity is at an all-time high.* In response, Pioneer Group, a specialist in life science infrastructure and venture building, is ramping up its support for start-up businesses tackling planetary health challenges.

This year, Pioneer is accelerating the development of planetary health innovations through a comprehensive programme of events, a “Golden Ticket” competition, venture development support, specialist lab space, and access to its expert network.